Category: AbbVie
-
AbbVie tumbles after new schizophrenia drug fails two trials
•
(Bloomberg) — AbbVie Inc. shares fell. (ABBV) fell by the most in three years after two mid-stage trials of its schizophrenia drug failed to meet their primary target, a blow to the company’s $8.7 billion acquisition of Cerevel Therapeutics earlier this year. . Most read from Bloomberg AbbVie said Monday…